Registration Dossier

Administrative data

Description of key information

CAS 756-13-8 had an LD50 Oral greater than 2000 mg/kg bw, an LD50 Dermal greater than 2000 mg/kg bw and an LC50 Inhalation greater than 98658 ppm
The Oral LD50 is greater than 2000 mg/kg and weight gain during the study period was considered normal. The Dermal LD50 is greater than 2000 mg/kg and weight gain during study period was considered normal.
The Inhalation LC50 is greater than 98,658 ppm. There were no deaths. Treatment related exaggerated breathing was seen during the test period and in the first two hours after the test period. Breathing was normal in days 2-14 of the observation period. Weight gain was normal during the study period.
Cardiac Sensitization was evaluated in beagle dogs with the addition of adrenaline up to an air concentration of 15.4%. No signs of cardiac sensitization, which was determined by EKG monitoring, was seen in this test. The material is not a cardiac sensitizer up to 15.4%.
In the Eye Irritation/Corrosion study, slight conjunctival irritation was seen in one animal. This was completely resolved within 24 hours. No other signs of irritation were noted and the material is not considered to be an eye irritant.
In the Primary Skin Irritation study, no irritation was noted in any animal at any time point and the material is not considered to be a skin irritant.
A Buehler sensitization study was conducted. No skin reactions were seen in the challenge phase of the study and the material is not considered to be a sensitizer.

Key value for chemical safety assessment

Additional information

CAS 756-13-8 was administered by oral gavage at 2000 mg/kg bw according to OECD 423. No mortality was observed. Weight gain during the study period was considered normal. 

 

CAS 756-13-8 was administered dermally at 2000 mg/kg bw according to OECD 402. No mortality was observed and weight gain during study period was considered normal. Lethargy, hunched posture and/or other symptoms were observed in most animals but these resolved by day 4 in all but one animal.

 

Animals were exposed to a concentration of 98,658 ppm of CAS 756-13-8. No mortality was observed. Treatment related exaggerated breathing was seen during the test period and in the first two hours after the test period. Breathing was normal in days 2-14 of the observation period. Weight gain was normal during the study period.

Justification for classification or non-classification